76807-55-1

Basic information

• Product Name: Pyrido(3,2-d)pyrimidine-6-methanol, 2,4-dichloro-, acetate (ester)
• Synonyms: Pyrido(3,2-d)pyrimidine-6-methanol, 2,4-dichloro-, acetate (ester);(2,4-DICHLOROPYRIDO[3,2-D]PYRIMIDIN-6-YL)METHYL ACETATE
• CAS NO: 76807-55-1
• Molecular Formula: C₁₀H₇Cl₂N₃O₂
• Molecular Weight: 272.09
• Mol File: 76807-55-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 349.6°C at 760 mmHg
• Flash Point: 165.2°C
• Appearance: /
• Density: 1.512g/cm³
• Vapor Pressure: 4.65E-05mmHg at 25°C
• Refractive Index: 1.631
• CAS DataBase Reference: Pyrido(3,2-d)pyrimidine-6-methanol, 2,4-dichloro-, acetate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrido(3,2-d)pyrimidine-6-methanol, 2,4-dichloro-, acetate (ester)(76807-55-1)
• EPA Substance Registry System: Pyrido(3,2-d)pyrimidine-6-methanol, 2,4-dichloro-, acetate (ester)(76807-55-1)

Safety Data

• Hazardous Substances Data: 76807-55-1(Hazardous Substances Data)

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 46, p. 1777, 1981 DOI: 10.1021/jo00322a004

InChI:InChI=1/C10H7Cl2N3O2/c1-5(16)17-4-6-2-3-7-8(13-6)9(11)15-10(12)14-7/h2-3H,4H2,1H3

Upstream product

• 76807-54-0 6-(Acetoxymethyl)-2,4-dioxopyrido<3,2-d>pyrimidine 
• 76807-54-0 Acetic acid 2,4-dihydroxy-pyrido[3,2-d]pyrimidin-6-ylmethyl ester 
• 2499-96-9 2,4-dioxo-6-methylpyrido<3,2-d>pyrimidine 
• 76807-53-9 6-Methyl-5-oxy-pyrido[3,2-d]pyrimidine-2,4-diol 
• 2499-96-9 2,4-Dioxo-6-methylpyrido<3,2-d>pyrimidine 
• 76807-53-9 2,4-Dioxo-6-methylpyrido<3,2-d>pyrimidine 5-Oxide 

Downstream Products

• 175410-92-1 6-Phenylaminomethyl-pyrido[3,2-d]pyrimidine-2,4-diamine 
• 175411-00-4 6-[(2-Chloro-phenylamino)-methyl]-pyrido[3,2-d]pyrimidine-2,4-diamine 
• 175410-94-3 6-[(2-Methoxy-phenylamino)-methyl]-pyrido[3,2-d]pyrimidine-2,4-diamine 
• 175411-10-6 6-[(2,5-Dichloro-phenylamino)-methyl]-pyrido[3,2-d]pyrimidine-2,4-diamine 
• 175411-12-8 6-[(2,6-Dichloro-phenylamino)-methyl]-pyrido[3,2-d]pyrimidine-2,4-diamine 
• 175411-15-1 6-[(3,4,5-Trichloro-phenylamino)-methyl]-pyrido[3,2-d]pyrimidine-2,4-diamine 

Relevant articles and documents

Tetrahydrofurfuroxy folic acid analogue synthetic method

The invention relates to a novel method for synthesis of tetrahydrofolic acid analogues, and mainly solves the problems of uneasily controllable reaction conditions and many produced by products in a conventional synthesis method. A series of tetrahydrofolic acid analogues are prepared by employing 5-aminouracil or 2,4,5,6-tetraaminopyrimidine, 2,5,6-triamino-4-hydroxypyrimidine as an initial raw material and combining the steps of cyclization, oxidation, chlorination, ammonolysis, catalytic hydrogenation reduction, intramolecular cyclization, aziridine ring opening, nucleophilic substitution, ethoxycarbonyl hydrolysis, etc. Compared with a conventional synthesis method, the novel method provided by the invention has the characteristics of mild and stable reaction conditions, few by-products, wide application range, etc.

PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Pyrimidine derivatives and methods of making and using these derivatives

This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed.